Jimmy Lee, MD
Cornea and External Diseases Specialist · Irvine, CANPI 1306045802
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.
Across 275 payments — averaging $61.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$2K
- Lensar, Inc.$2K
- Sight Sciences, Inc.$2K
- Bausch & Lomb Americas Inc.$1K
- Carl Zeiss Meditec, Inc.$1K
- plus $5K from 22 others
What the payments were for
- Consulting fees$1,1257%
- Speaking & faculty fees$320%
- Travel & lodging$3522%
- Food & beverage$15,37391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 41 | $2,680 |
| AbbVie(2 entities) | 67 | $2,254 |
| Lensar, Inc. | 1 | $2,250 |
| Sight Sciences, Inc. | 26 | $1,888 |
| Bausch & Lomb Americas Inc. | 37 | $1,285 |
| Carl Zeiss Meditec, Inc. | 1 | $1,125 |
| Glaukos Corporation | 11 | $878 |
| Carl Zeiss Meditec USA, Inc. | 6 | $650 |
| Dompe US, Inc. | 18 | $560 |
| Aerie Pharmaceuticals, Inc. | 5 | $518 |
| Oyster Point Pharma, Inc. | 3 | $323 |
| Beaver-visitec International, Inc. | 2 | $284 |
| Nova Eye, Inc. | 2 | $280 |
| Mallinckrodt Hospital Products Inc. | 7 | $264 |
| Biotissue Holdings Inc. | 3 | $256 |
| Novartis | 14 | $255 |
| Rxsight Inc | 6 | $229 |
| Sun Pharmaceutical Industries Inc. | 6 | $156 |
| Ivantis, Inc | 1 | $143 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $128 |
| Apellis Pharmaceuticals, Inc. | 1 | $123 |
| Ocular Therapeutix, Inc. | 3 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $84 |
| Shire North American Group Inc | 2 | $41 |
| Thea Pharma Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$2,250
- VisuMax$1,477
- MEL 90$1,125
- CIRRUS HD-OCT$1,125
- CALLISTO eye$1,125
- IOLMaster 700$1,125
- OMNI(R) SURGICAL SYSTEM (US)$970
- Clareon$590
- Rhopressa$494
- Rocklatan$494
- DURYSTA$474
- Wavelight Refractive Suite$379
- TYRVAYA$311
- MIEBO$253
- ARGOS$244
- Oxervate$243
- Clareon PanOptix Pro$238
- QUATERA 700$225
- Centurion$148
- AcrySof IQ PanOptix UV IOL$147
How this compares
$16,882 in reported general payments places this provider in the 75th percentile of 50 cornea and external diseases specialist providers in California.
See all cornea and external diseases specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $567,207 |
| RestasisCyclosporine | 91 | $69,923 |
| XiidraLifitegrast | 35 | $32,878 |
| MieboPerfluorohexyloctane/Pf | 32 | $30,113 |
| Bromfenac Sodium | 90 | $10,724 |
| LumiganBimatoprost | 24 | $10,641 |
| VyzultaLatanoprostene Bunod | 29 | $9,876 |
| Cyclosporine | 24 | $9,862 |
| Prednisolone Acetate | 226 | $8,089 |
| ProlensaBromfenac Sodium | 21 | $6,898 |
| MoxifloxacinMoxifloxacin Hcl | 218 | $4,886 |
| Lotemax SmLoteprednol Etabonate | 15 | $3,700 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,150 |
| Timolol MaleateTimolol Maleate/Pf | 14 | $2,489 |
| Brimonidine Tartrate | 15 | $2,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $560 | $567,20720 claims |
| AbbVieRestasis, Lumigan | $2,254 | $80,563115 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,285 | $72,86696 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $84 | $10,59836 claims |
| AlconSimbrinza | $2,680 | $3,15016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 cornea and external diseases specialist providers in California.
Other cornea and external diseases specialist in Irvine
- Sumit GargIrvine$808K
- Matthew WadeIrvine$38K
- Lawrence ChaoIrvine$36K
- Elizabeth ShenIrvine$11K
- Rakhi MelvaniIrvine$10K
- Jillian ChongBeverly Hills$113K
- Tyson KimSan Francisco$91K
- Edward MancheStanford$78K
- Michael SavetskyCulver City$63K
- Michael SaidelSonoma$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.